NewAmsterdam Pharma (NASDAQ:NAMS) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of NewAmsterdam Pharma (NASDAQ:NAMS) from a hold rating to a sell rating in a research report report published on Saturday morning.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Guggenheim raised their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday. Needham & Company LLC upped their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday. Finally, HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Trading Up 1.7%

NAMS opened at $36.17 on Friday. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00. The stock has a fifty day moving average price of $33.98 and a 200-day moving average price of $32.78. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of -20.91 and a beta of 0.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 75,117 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57. Following the transaction, the chief accounting officer owned 15,000 shares in the company, valued at approximately $543,150. This represents a 83.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00. Following the sale, the insider owned 73,481 shares of the company’s stock, valued at approximately $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 298,647 shares of company stock worth $10,236,050 over the last three months. Corporate insiders own 20.84% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jennison Associates LLC boosted its stake in shares of NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Atle Fund Management AB raised its holdings in NewAmsterdam Pharma by 23.2% in the 3rd quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after purchasing an additional 36,402 shares during the period. Keybank National Association OH acquired a new position in NewAmsterdam Pharma in the 3rd quarter worth about $455,000. Franklin Resources Inc. boosted its position in NewAmsterdam Pharma by 30.6% during the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after purchasing an additional 78,300 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its holdings in NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.